Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 65

1.

Stem Cell Businesses and Right to Try Laws.

Sipp D, Turner L, Rasko JEJ.

Cell Stem Cell. 2019 Sep 5;25(3):304-305. doi: 10.1016/j.stem.2019.08.012. No abstract available.

PMID:
31491393
2.

Downgrading of regulation in regenerative medicine.

Sipp D, Sleeboom-Faulkner M.

Science. 2019 Aug 16;365(6454):644-646. doi: 10.1126/science.aax6184. No abstract available.

PMID:
31416952
3.

The politics of evidence in online illness narratives: An analysis of crowdfunding for purported stem cell treatments.

Tanner C, Munsie M, Sipp D, Turner L, Wheatland C.

Health (London). 2019 Jul;23(4):436-457. doi: 10.1177/1363459319829194. Epub 2019 Feb 19.

PMID:
30782021
4.

Tackling Ethical Challenges of Premature Delivery of Stem Cell-Based Therapies: ISSCR 2018 Annual Meeting Focus Session Report.

Sugarman J, Barker RA, Kerridge I, Lysaght T, Pellegrini G, Sipp D, Tanner C.

Stem Cell Reports. 2018 Nov 13;11(5):1021-1025. doi: 10.1016/j.stemcr.2018.10.020.

5.

Clear up this stem-cell mess.

Sipp D, Robey PG, Turner L.

Nature. 2018 Sep;561(7724):455-457. doi: 10.1038/d41586-018-06756-9. No abstract available.

PMID:
30258150
6.

Emerging stem cell ethics.

Sipp D, Munsie M, Sugarman J.

Science. 2018 Jun 22;360(6395):1275. doi: 10.1126/science.aau4720. No abstract available.

PMID:
29930112
7.

Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.

Sipp D.

Perspect Biol Med. 2018;61(1):25-41. doi: 10.1353/pbm.2018.0025.

PMID:
29805146
8.

No Vacillation on HPV Vaccination.

Sipp D, Frazer IH, Rasko JEJ.

Cell. 2018 Mar 8;172(6):1163-1167. doi: 10.1016/j.cell.2018.02.045.

9.

Can civil lawsuits stem the tide of direct-to-consumer marketing of unproven stem cell interventions.

Horner C, Tenenbaum E, Sipp D, Master Z.

NPJ Regen Med. 2018 Feb 19;3:5. doi: 10.1038/s41536-018-0043-6. eCollection 2018. Review.

10.

Japan Strengthens Regenerative Medicine Oversight.

Sipp D, Okano H.

Cell Stem Cell. 2018 Feb 1;22(2):153-156. doi: 10.1016/j.stem.2018.01.001.

11.

Rejuvenating Regenerative Medicine Regulation.

Charo RA, Sipp D.

N Engl J Med. 2018 Feb 8;378(6):504-505. doi: 10.1056/NEJMp1715736. Epub 2018 Jan 10. No abstract available.

PMID:
29320637
12.

The malignant niche: safe spaces for toxic stem cell marketing.

Sipp D.

NPJ Regen Med. 2017 Dec 19;2:33. doi: 10.1038/s41536-017-0036-x. eCollection 2017. Review.

13.

A blueprint for the next generation of ELSI research, training, and outreach in regenerative medicine.

Illes J, Sipp D, Kleiderman E, Benjaminy S, Isasi R, Lomax G, Master Z, McCormick J, Ogbogu U, Ravitsky V, Robillard JM, Rossi F, Wilson B, Zarzeczny A.

NPJ Regen Med. 2017 Jul 5;2:21. doi: 10.1038/s41536-017-0026-z. eCollection 2017. Review.

14.

Identity and ownership issues in the regulation of autologous cells.

Sipp D.

Regen Med. 2017 Oct;12(7):827-838. doi: 10.2217/rme-2017-0063. Epub 2017 Nov 8.

PMID:
29115180
15.

Industry Responsibilities in Tackling Direct-to-Consumer Marketing of Unproven Stem Cell Treatments.

Master Z, Fu W, Paciulli D, Sipp D.

Clin Pharmacol Ther. 2017 Aug;102(2):177-179. doi: 10.1002/cpt.704. Epub 2017 Jul 10. Review.

PMID:
28695633
16.

Marketing of unproven stem cell-based interventions: A call to action.

Sipp D, Caulfield T, Kaye J, Barfoot J, Blackburn C, Chan S, De Luca M, Kent A, McCabe C, Munsie M, Sleeboom-Faulkner M, Sugarman J, van Zimmeren E, Zarzeczny A, Rasko JEJ.

Sci Transl Med. 2017 Jul 5;9(397). pii: eaag0426. doi: 10.1126/scitranslmed.aag0426. Review.

17.

Show drugs work before selling them.

Sipp D, McCabe C, Rasko JE.

Nature. 2017 Mar 8;543(7644):174-175. doi: 10.1038/543174a. No abstract available.

PMID:
28277530
18.

Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.

Lysaght T, Kerridge IH, Sipp D, Porter G, Capps BJ.

J Bioeth Inq. 2017 Jun;14(2):261-273. doi: 10.1007/s11673-017-9776-y. Epub 2017 Feb 28. Review.

PMID:
28247202
19.

Global Distribution of Businesses Marketing Stem Cell-Based Interventions.

Berger I, Ahmad A, Bansal A, Kapoor T, Sipp D, Rasko JEJ.

Cell Stem Cell. 2016 Aug 4;19(2):158-162. doi: 10.1016/j.stem.2016.07.015.

20.

Bioethics in China: No wild east.

Sipp D, Pei D.

Nature. 2016 Jun 23;534(7608):465-7. doi: 10.1038/534465a. No abstract available. Erratum in: Nature. 2016 Jul 21;535(7612):350.

PMID:
27337327
21.

Cell Churches and Stem Cell Marketing in South Korea and the United States.

Sipp D.

Dev World Bioeth. 2017 Dec;17(3):167-172. doi: 10.1111/dewb.12120. Epub 2016 May 23.

PMID:
27214044
22.

Policy: Global standards for stem-cell research.

Kimmelman J, Hyun I, Benvenisty N, Caulfield T, Heslop HE, Murry CE, Sipp D, Studer L, Sugarman J, Daley GQ.

Nature. 2016 May 19;533(7603):311-3. doi: 10.1038/533311a. No abstract available.

PMID:
27193661
23.

Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines.

Daley GQ, Hyun I, Apperley JF, Barker RA, Benvenisty N, Bredenoord AL, Breuer CK, Caulfield T, Cedars MI, Frey-Vasconcells J, Heslop HE, Jin Y, Lee RT, McCabe C, Munsie M, Murry CE, Piantadosi S, Rao M, Rooke HM, Sipp D, Studer L, Sugarman J, Takahashi M, Zimmerman M, Kimmelman J.

Stem Cell Reports. 2016 Jun 14;6(6):787-797. doi: 10.1016/j.stemcr.2016.05.001. Epub 2016 May 12.

24.

New ISSCR guidelines: clinical translation of stem cell research.

Kimmelman J, Heslop HE, Sugarman J, Studer L, Benvenisty N, Caulfield T, Hyun I, Murry CE, Sipp D, Daley GQ.

Lancet. 2016 May 14;387(10032):1979-81. No abstract available.

PMID:
27179752
25.

SCIENTIFIC COMMUNITY. Confronting stem cell hype.

Caulfield T, Sipp D, Murry CE, Daley GQ, Kimmelman J.

Science. 2016 May 13;352(6287):776-7. doi: 10.1126/science.aaf4620. Epub 2016 May 12. No abstract available.

PMID:
27174977
26.

Undertested and Overpriced: Japan Issues First Conditional Approval of Stem Cell Product.

McCabe C, Sipp D.

Cell Stem Cell. 2016 Apr 7;18(4):436-7. doi: 10.1016/j.stem.2016.03.006. No abstract available.

27.

Paolo Bianco (1955-2015).

Robey PG, Riminucci M, Boyde A, Sipp D.

Cell Stem Cell. 2015 Dec 3;17(6):649-50. No abstract available.

28.

Conditional approval: Japan lowers the bar for regenerative medicine products.

Sipp D.

Cell Stem Cell. 2015 Apr 2;16(4):353-6. doi: 10.1016/j.stem.2015.03.013.

29.

Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications: International Stem Cell Banking Initiative (ISCBI).

Andrews PW, Baker D, Benvinisty N, Miranda B, Bruce K, Brüstle O, Choi M, Choi YM, Crook JM, de Sousa PA, Dvorak P, Freund C, Firpo M, Furue MK, Gokhale P, Ha HY, Han E, Haupt S, Healy L, Hei DJ, Hovatta O, Hunt C, Hwang SM, Inamdar MS, Isasi RM, Jaconi M, Jekerle V, Kamthorn P, Kibbey MC, Knezevic I, Knowles BB, Koo SK, Laabi Y, Leopoldo L, Liu P, Lomax GP, Loring JF, Ludwig TE, Montgomery K, Mummery C, Nagy A, Nakamura Y, Nakatsuji N, Oh S, Oh SK, Otonkoski T, Pera M, Peschanski M, Pranke P, Rajala KM, Rao M, Ruttachuk R, Reubinoff B, Ricco L, Rooke H, Sipp D, Stacey GN, Suemori H, Takahashi TA, Takada K, Talib S, Tannenbaum S, Yuan BZ, Zeng F, Zhou Q.

Regen Med. 2015;10(2 Suppl):1-44. doi: 10.2217/rme.14.93. No abstract available.

PMID:
25675265
30.

Enabling consistency in pluripotent stem cell-derived products for research and development and clinical applications through material standards.

French A, Bravery C, Smith J, Chandra A, Archibald P, Gold JD, Artzi N, Kim HW, Barker RW, Meissner A, Wu JC, Knowles JC, Williams D, García-Cardeña G, Sipp D, Oh S, Loring JF, Rao MS, Reeve B, Wall I, Carr AJ, Bure K, Stacey G, Karp JM, Snyder EY, Brindley DA.

Stem Cells Transl Med. 2015 Mar;4(3):217-23. doi: 10.5966/sctm.2014-0233. Epub 2015 Feb 3. Review.

31.

Regulation: Sell help not hope.

Bianco P, Sipp D.

Nature. 2014 Jun 19;510(7505):336-7. No abstract available.

PMID:
24955467
32.

Oversight for clinical uses of autologous adult stem cells: lessons from international regulations.

Lysaght T, Kerridge I, Sipp D, Porter G, Capps BJ.

Cell Stem Cell. 2013 Dec 5;13(6):647-51. doi: 10.1016/j.stem.2013.11.013.

33.

The implementation of novel collaborative structures for the identification and resolution of barriers to pluripotent stem cell translation.

Brindley DA, French A, Suh J, Roberts M, Davies B, Pinedo-Villanueva R, Wartolowska K, Rooke K, Kramm A, Judge A, Morrey M, Chandra A, Hurley H, Grover L, Bingham I, Siegel B, Rattley MS, Buckler RL, McKeon D, Krumholz K, Hook L, May M, Rikabi S, Pigott R, Morys M, Sabokbar A, Titus E, Laabi Y, Lemaitre G, Zahkia R, Sipp D, Horne R, Bravery C, Williams D, Wall I, Snyder EY, Karp JM, Barker RW, Bure K, Carr AJ, Reeve B.

Stem Cells Dev. 2013 Dec;22 Suppl 1:63-72. doi: 10.1089/scd.2013.0403.

34.

Global bionetworks and challenges in regulating autologous adult stem cells.

Lysaght T, Kerridge I, Sipp D, Porter G, Capps BJ.

Am J Med. 2013 Nov;126(11):941-3. doi: 10.1016/j.amjmed.2013.06.031. No abstract available.

PMID:
24157285
35.

Tissue interactions in neural crest cell development and disease.

Takahashi Y, Sipp D, Enomoto H.

Science. 2013 Aug 23;341(6148):860-3. doi: 10.1126/science.1230717. Review.

PMID:
23970693
36.

Direct-to-consumer stem cell marketing and regulatory responses.

Sipp D.

Stem Cells Transl Med. 2013 Sep;2(9):638-40. doi: 10.5966/sctm.2013-0040. Epub 2013 Aug 9.

37.

Advocacy: How to hasten open access.

Swan A, Cockerill M, Sipp D.

Nature. 2013 Mar 28;495(7442):442-3. doi: 10.1038/495442a. No abstract available.

PMID:
23538813
38.

Pay-to-participate funding schemes in human cell and tissue clinical studies.

Sipp D.

Regen Med. 2012 Nov;7(6 Suppl):105-11. doi: 10.2217/rme.12.75. Review.

39.

Stem cells. U.S. regulation of stem cells as medical products.

Sipp D, Turner L.

Science. 2012 Dec 7;338(6112):1296-7. doi: 10.1126/science.1229918. No abstract available.

PMID:
23224541
40.

Ethical and policy issues in the clinical translation of stem cells: report of a focus session at the ISSCR Tenth Annual Meeting.

Kato K, Kimmelman J, Robert J, Sipp D, Sugarman J.

Cell Stem Cell. 2012 Dec 7;11(6):765-7. doi: 10.1016/j.stem.2012.11.004.

41.

Disclosure and management of research findings in stem cell research and banking: policy statement.

Isasi R, Knoppers BM, Andrews PW, Bredenoord A, Colman A, Hin LE, Hull S, Kim OJ, Lomax G, Morris C, Sipp D, Stacey G, Wahlstrom J, Zeng F; International Stem Cell Forum Ethics Working Party.

Regen Med. 2012 May;7(3):439-48. doi: 10.2217/rme.12.23.

PMID:
22594334
42.

Stem cell science on the rise in China.

Yuan W, Sipp D, Wang ZZ, Deng H, Pei D, Zhou Q, Cheng T.

Cell Stem Cell. 2012 Jan 6;10(1):12-5. doi: 10.1016/j.stem.2011.12.002. Review.

43.

Global update: Japan.

Sipp D.

Regen Med. 2011 Nov;6(6 Suppl):160-2. doi: 10.2217/rme.11.65. Review.

44.

The unregulated commercialization of stem cell treatments: a global perspective.

Sipp D.

Front Med. 2011 Dec;5(4):348-55. doi: 10.1007/s11684-011-0150-x. Epub 2011 Oct 1. Review.

PMID:
21964637
45.

Global challenges in stem cell research and the many roads ahead.

Sipp D.

Neuron. 2011 May 26;70(4):573-6. doi: 10.1016/j.neuron.2011.05.008. Review.

46.

New IJH guidelines highlight greater transparency.

Sipp D, Suda T.

Int J Hematol. 2011 Apr;93(4):411-412. doi: 10.1007/s12185-011-0815-x. No abstract available.

PMID:
21465118
47.

Stem cell stratagems in alternative medicine.

Sipp D.

Regen Med. 2011 May;6(3):407-14. doi: 10.2217/rme.11.13. Epub 2011 Mar 31. Review.

48.

2010 International Forum on Stem Cells (November 11-13; Tianjin, China).

Sipp D, Wang Z, Yuan W.

Stem Cell Rev Rep. 2011 Sep;7(3):479-81. doi: 10.1007/s12015-011-9246-6. No abstract available.

PMID:
21365255
49.

Publishing SNP genotypes of human embryonic stem cell lines: policy statement of the International Stem Cell Forum Ethics Working Party.

Knoppers BM, Isasi R, Benvenisty N, Kim OJ, Lomax G, Morris C, Murray TH, Lee EH, Perry M, Richardson G, Sipp D, Tanner K, Wahlström J, de Wert G, Zeng F.

Stem Cell Rev Rep. 2011 Sep;7(3):482-4. doi: 10.1007/s12015-010-9226-2.

50.

Patients beware: commercialized stem cell treatments on the web.

Taylor PL, Barker RA, Blume KG, Cattaneo E, Colman A, Deng H, Edgar H, Fox IJ, Gerstle C, Goldstein LS, High KA, Lyall A, Parkman R, Pitossi FJ, Prentice ED, Rooke HM, Sipp DA, Srivastava A, Stayn S, Steinberg GK, Wagers AJ, Weissman IL.

Cell Stem Cell. 2010 Jul 2;7(1):43-9. doi: 10.1016/j.stem.2010.06.001. Epub 2010 Jun 17.

Supplemental Content

Support Center